Currently browsing: Community News

CAC2 Childhood Cancer Community News Digest (November 22-28)

Assorted news from last week: A primer on where the Centers for Medicare and Medicaid Services see Medicaid and the Children’s Health Insurance Program (CHIP) heading in the future. Based on a Health Affairs commentary from Brooks-LaSure and Tsai, the three key priority areas are (1) coverage and access, (2) equity, and (3) innovation and whole-person care. CAC2 Supporting Organization Oncoheroes Biosciences has been awarded to be part of the 1st generation of companies accelerated in the #BCNHealthBooster, an initiative promoted by the Parc Científic de Barcelona (PCB) of Universitat de Barcelona and BarcelonaCityCouncil, with the collaboration of Barcelona Activa […]

Read more

CAC2 Childhood Cancer Community News Digest (November 15-21)

Assorted news from last week: Provocative article written by pediatric cancer advocates, including several CAC2 members — innovation can be crippled by commercialization — meaning next better treatments are completely at the mercy of companies who now have income from drug sales from approved drugs and may not agree to provide the drug for further testing in combinations, etc. To encourage drug companies (sponsors) to develop effective treatments for childhood cancer, authorities in the United States (US) and Europe have made new rules for drug development, and this team from Pfizer has some recommendations to help sponsors maximize their chances of […]

Read more

CAC2 Childhood Cancer Community News Digest (November 8-14)

Assorted news from last week: Save the Date:  CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies reported their work in the most recent edition  of European Journal of Cancer.  The Forum was sponsored by ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. CAC2 Member Oncoheroes Biosciences Inc., a biotech focused on advancing new therapies for childhood cancer, has out-licensed worldwide the adult rights to Notable Labs, Inc. (“Notable”), a clinical-stage predictive precision medicine company.  Under the terms of this […]

Read more

CAC2 Childhood Cancer Community News Digest (November 1-7)

Assorted news from last week: Save the Date:  CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. The Children’s Brain Tumor Network (CBTN) has collected tumor samples from patients at 26 member institutions all over the world. Through funding from the Childhood Cancer Data Initiative of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).  CBTN will procure molecular characterization for thousands of these brain tumor samples providing an unprecedented level of insight into devastating cancers and paving the way for future therapeutic interventions. Compassionate use case of DAY101 demonstrates a complete response in a pediatric patient with a recurrent spindle cell sarcoma harboring a BRAF gene fusion. Despite the relative rarity […]

Read more

CAC2 Childhood Cancer Community News Digest (October 25-31)

Assorted news from last week: Save the Date:  CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. The World Health Organization (WHO) has published the consensus of a set of indicators to evaluate and monitor the development of palliative care worldwide. The report was presented last week at the 17th Palliative Care World Congress in a joint symposium of the WHO and the European Association for Palliative Care. Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher […]

Read more

CAC2 Childhood Cancer Community News Digest (October 18-24)

Assorted news from last week: CAC2 Ethics Think Tank presented a paper entitled Cultivating Ethically Sustainable Relationships with Stakeholders When Non-Profits Fund Pediatric Cancer Clinical Trials at SIOP. The National Cancer Institute and Cancer Research UK sponsors the Cancer Grand Challenge each year.  This year the scientific committee narrowed the 169 innovative ideas down to a shortlist of just 11 teams, who will now compete for a share of £80m.  A newly launched childhood cancer research initiative called the “Virtual Child” is a finalist. This is a global project that harnesses the power of technology to transform the treatment of pediatric solid tumors. […]

Read more

CAC2 Childhood Cancer Community News Digest (October 11-17)

Assorted news from last week: CAC2 Ethics Think Tank will present a paper entitled Cultivating Ethically Sustainable Relationships with Stakeholders When Non-Profits Fund Pediatric Cancer Clinical Trials at SIOP 2021 (on Saturday, October 23rd). The National Childhood Cancer Registry (NCCR) issued an update this week of frequently requested incidence statistics based on the International Classification of Childhood Cancer (ICCC) using data from . It includes number of cases, age-adjusted incidence rates, and trends by characteristics including single age at diagnosis, sex, race/ethnicity, period of diagnosis, and cancer site and subsites.  The report contains data on 232,859* tumors in children under age […]

Read more

CAC2 Childhood Cancer Community News Digest (October 4-10)

Assorted news from last week: The FDA has granted a rare pediatric disease designation (RPDD) to lutetium-177(177Lu)-omburtamab-DTPA for use as a potential therapeutic option in pediatric patients with medulloblastoma, according to an announcement from CAC2 Member Y-mAbs Therapeutics, Inc.,  developer of the product. Cancers in children, adolescents and young adults can be resistant to medical treatments or recur even when initial treatments appear successful.  Findings of a 10-year study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and in collaboration with the Beat Childhood Cancer Research Consortium, suggest that deeper genomic analysis and therapies […]

Read more

CAC2 Childhood Cancer Community News Digest (September 27-October 3)

Assorted news from last week: CAC2 Member Mary Beth Collins, highlights the importance of Childhood Cancer License Plates, how they amplify awareness efforts, the advocacy required to create these plates and CAC2’s Childhood Cancer License Plate awareness effort. Gavin Lindberg had an Opinion Piece published in The Washington Post titled “The US Should Invest in Children’s Health.” From the New England Journal of Medicine correspondence: Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma Mount Sinai researchers have developed a therapy that shows promise against acute myeloid leukemia. A new study based on patient samples collected over the past decade by [...] Read more

CAC2 Childhood Cancer Community News Digest (September 13-26)

Assorted news from the last two weeks: In recognition of Childhood Cancer Awareness Month, NCI Director Ned Sharpless reflected on the progress that’s been made against cancers that largely affect children. New Jersey established the “Pediatric Cancer Research Fund” and an advisory board within the New Jersey State Commission on Cancer Research for disbursement of monies deposited in the fund and provides voluntary contributions by taxpayers on gross income tax returns for pediatric cancer research. Additionally, S3724 appropriates $5 million to the New Jersey Pediatric Cancer Fund. A study of children with cancer identified an association between physical activity, fatigue, […]

Read more